Answers are grounded in this paper and cite their sources.
Basal release of pre-labeled, stored tritiated rat growth hormone ([3H]rGH) from perfused rat pituitary explants is a constant fraction of pituitary [LH]rGH content. Synthetic somatostatin (SRIF) inhibits the release of pre-labeled, stored [3H]rGH in a dose-dependent fashion. Prolonged exposure to SRIF results in an immediate and continuous inhibition of [3H]rGH release. In the in vitro perifusion system, the maximal inhibition, which is achieved with 25 nM SRIF, results in a rate of [3H]rGH release which is 30 to 40 per cent of basal release. Pulses of SRIF produce inhibition of [3H]rGH release followed by rebound release after withdrawal of SRIF. When the time of exposure to SRIF is held constant, both the SRIF-induced inhibition and the rebound release of [3H]rGH are dose-dependent. A similar progressive response is seen when a constant SRIF concentration is pulsed for variable periods of time. There is no net inhibition of [3H]rGH release by pulses of SRIF.
No takes yet. Share an insight, caveat, or question.
Max E. Stachura (1976) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: